

Report of transactions in Zealand's shares and related securities by executives and their related parties

Copenhagen, 16 November 2015 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand must disclose information on transactions with the company's shares and related securities by executives and persons/companies closely related to them.

With reference to the above, Zealand announces it has received information on the following transactions for disclosure:

Name:	Christian Thorkildsen
Reason:	Employee elected member of the Board of Directors
Issuer:	Zealand Pharma A/S
Designation:	Shares
ISIN Code:	DK0060257814
Transaction:	Exercise of warrants
Trading Date:	13 November 2015
Market:	Nasdaq Copenhagen
Number:	27,000
Price:	DKK 77.00
Total value:	DKK 2,079,000.00

Name:	Helle Størum
Reason:	Employee elected member of the Board of Directors
Issuer:	Zealand Pharma A/S
Designation:	Shares
ISIN Code:	DK0060257814
Transaction:	Exercise of warrants
Trading Date:	13 November 2015
Market:	Nasdaq Copenhagen
Number:	7,500
Price:	DKK 77.00
Total value:	DKK 577,500.00



Name:	Jens Peter Stenvang
Reason:	Employee elected member of the Board of Directors
Issuer:	Zealand Pharma A/S
Designation:	Shares
ISIN Code:	DK0060257814
Transaction:	Exercise of warrants
Trading Date:	13 November 2015
Market:	Nasdaq Copenhagen
Number:	5,000
Price:	DKK 77.00
Total value:	DKK 385,000.00



For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia[®] by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus[®]) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016.

The proprietary pipeline includes; *danegaptide* for ischemic reperfusion Injuries in Phase II development; *ZP1848* for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, *ZP4207*, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as *several preclinical peptide therapeutics*.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma